Journal
SCHIZOPHRENIA BULLETIN
Volume 49, Issue 4, Pages 1055-1066Publisher
OXFORD UNIV PRESS
DOI: 10.1093/schbul/sbad029
Keywords
ultra-high risk; basic symptoms COGDIS; prodrome; indicated prevention; psychotherapy; second-generation antipsychotics
Categories
Ask authors/readers for more resources
This study compared the effectiveness of Cognitive-Behavioral Therapy (CBT) and Second-Generation Antipsychotics (SGAs) as the first-line treatments for individuals at clinical high risk for psychosis (CHRp). The results showed that neither CBT nor SGAs had significant advantages over the placebo in preventing the transition to psychosis. Therefore, low-dose aripiprazole and CBT did not offer additional benefits over clinical management and placebo.
Background There is limited knowledge of whether cognitive-behavioral therapy (CBT) or second-generation antipsychotics (SGAs) should be recommended as the first-line treatment in individuals at clinical high risk for psychosis (CHRp). Hypothesis To examine whether individual treatment arms are superior to placebo and whether CBT is non-inferior to SGAs in preventing psychosis over 12 months of treatment. Study Design PREVENT was a blinded, 3-armed, randomized controlled trial comparing CBT to clinical management plus aripiprazole (CM + ARI) or plus placebo (CM + PLC) at 11 CHRp services. The primary outcome was transition to psychosis at 12 months. Analyses were by intention-to-treat. Study Results Two hundred eighty CHRp individuals were randomized: 129 in CBT, 96 in CM + ARI, and 55 in CM + PLC. In week 52, 21 patients in CBT, 19 in CM + ARI, and 7 in CM + PLC had transitioned to psychosis, with no significant differences between treatment arms (P = .342). Psychopathology and psychosocial functioning levels improved in all treatment arms, with no significant differences. Conclusions The analysis of the primary outcome transition to psychosis at 12 months and secondary outcomes symptoms and functioning did not demonstrate significant advantages of the active treatments over placebo. The conclusion is that within this trial, neither low-dose aripiprazole nor CBT offered additional benefits over clinical management and placebo.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available